Johnson & Johnson $JNJ Position Lowered by Commerzbank Aktiengesellschaft FI

Key Points

• Commerzbank Aktiengesellschaft FI reduced its stake in Johnson & Johnson by 13.3%, selling 128,991 shares and now holding 840,160 shares, which represent 2.9% of its investment portfolio.
• Johnson & Johnson recently announced a quarterly dividend of $1.30, resulting in an annualized dividend of $5.20 and a yield of 2.7%.
• Several analysts have updated their price targets for Johnson & Johnson, with Citigroup raising theirs from $200.00 to $213.00, and Royal Bank of Canada setting a target of $209.00.

Commerzbank Aktiengesellschaft FI lessened its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 13.3% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 840,160 shares of the company's stock after selling 128,991 shares during the quarter. Johnson & Johnson makes up about 2.9% of Commerzbank Aktiengesellschaft FI's investment portfolio, making the stock its 9th largest position. Commerzbank Aktiengesellschaft FI's holdings in Johnson & Johnson were worth $128,334,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of JNJ. Brighton Jones LLC lifted its holdings in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after buying an additional 6,332 shares in the last quarter. Wealth Group Ltd. purchased a new stake in Johnson & Johnson during the first quarter valued at $218,000. GAMMA Investing LLC raised its stake in Johnson & Johnson by 48.0% during the first quarter. GAMMA Investing LLC now owns 43,508 shares of the company's stock valued at $7,215,000 after purchasing an additional 14,118 shares in the last quarter. Dodds Wealth LLC raised its stake in Johnson & Johnson by 15.6% during the first quarter. Dodds Wealth LLC now owns 3,576 shares of the company's stock valued at $593,000 after purchasing an additional 482 shares in the last quarter. Finally, Founders Grove Wealth Partners LLC raised its stake in Johnson & Johnson by 2.5% during the first quarter. Founders Grove Wealth Partners LLC now owns 6,886 shares of the company's stock valued at $1,142,000 after purchasing an additional 168 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Down 0.2%

JNJ stock opened at $190.66 on Friday. The company has a market capitalization of $459.16 billion, a PE ratio of 20.39, a P/E/G ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $192.10. The firm's 50-day moving average is $178.48 and its 200 day moving average is $163.77. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. On average, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on JNJ shares. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $209.00 price target on shares of Johnson & Johnson in a research note on Friday. Morgan Stanley upped their price target on shares of Johnson & Johnson from $176.00 to $178.00 and gave the company an "equal weight" rating in a research note on Friday. Citigroup upped their price target on shares of Johnson & Johnson from $200.00 to $213.00 and gave the company a "buy" rating in a research note on Tuesday. Barclays increased their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Finally, Guggenheim raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their target price for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have issued a Hold rating to the company's stock. According to MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus price target of $192.94.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.